Yunus DONDER, Saliha KARAGOZ EREN, Ebru AKAY, Fatos TEKELİOĞLU, Hatice KARAMAN

Results of concurrent HER2 (CERB-B2) staining in the primary tumor and lymph node metastasis in advanced stage gastric carcinoma

Aim: We hypothesized that tumor cells with metastatic capacity and nodal metastasis would exhibit prominent HER2 overexpression in gastric cancer for which intratumoral heterogeneity is highly variable. This study purposed to investigate the mismatch for HER2 immunohistochemical staining between the primary tumor cells and the metastatic cells in patients with advanced-stage gastric cancer.Material and Methods: A hundred and forty-four patients with advanced staged gastric cancer, and lymph node metastasis who underwent surgical resection were enrolled in this retrospective study. Primary tumor and lymph node metastasis underwent concurrent immunohistochemical staining for addressing the HER2 positivity. The concordance of HER2 positivity between the primary tumor samples and the lymph node metastases was investigated.Results: There was a significant difference in HER2 positivity rate among the well, moderate, and poorly differentiated carcinomas, which was primarily driven by the high HER2 overexpression in well-differentiated subgroup. HER2 positivity was highly frequent in stage 3 tumors, whereas HER2 was negative in the majority of the stage 4 tumors. Tumor size was also significantly larger insubjects without HER2 overexpression compared to those with HER overexpression [6 (IQR=4.88) cm vs. 5.25 (IQR=3.5) cm, p =0.037]. Concordance of primary tumors and the metastatic lymph nodes regarding HER2 positive IHC staining were 93.7%.Conclusion: HER2 might be positive in lymph node metastasis samples even if the primary tumor is negative for HER2. We suggest that HER2 IHC staining of the lymph node metastasis should be considered if the primary tumor is signet ring cell carcinoma, moderately or poorly differentiated, and negative for HER2 in subjects with gastric carcinoma and lymph node metastasis.

PDF

___

1. Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700-13.
2. Nadaf AS, Rani H, Dinesh US. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India. Asian Pac J Cancer Prev 2018;19:1381-5.
3. Torre LA, Bray F, Siegel RL,et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
4. Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. World J Gastroenterol 2016;22:4619-25.
5. Peng Z, Zou J, Zhang X, et al. HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chine J Cancer Res 2015;27:163-71.
6. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;28:687-97.
7. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010;78:26-33.
8. Sawaki A, Ohashi Y, Omuro Y, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 2012;15:313-22.
9. Huber AR, Buscaglia B, Koltz BR, et al. Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma: More Is Better. Am J Clin Pathol 2019;151:461-8.
10. Chen Y-C, Fang W-L, Wang R-F, et al. Clinicopathological variation of Lauren classification in gastric cancer. Pathol Oncol Res 2016;22:197-202.
11. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
12. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
13. Bartley AN, Washington MK, Ventura CB, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med 2016; 140:1345-63.
14. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
15. Feizy A, Karami A, Eghdamzamiri R, et al. HER2 expression status and prognostic, diagnostic, and demographic properties of patients with gastric cancer: a single center cohort study from Iran. Asian Pac J Cancer Prev 2018;19:1721-5.
16. Yildirim S, Dandin O, Durmus M, et al. C-erb-B2 (Her2/neu) Expression Rate And its Association with Clinicopathologic Parameters in Gastric Cancer. International Journal of Hematology and Oncology 2012;28:156-62.
17. Emre H, Tekin SB, Dogan H, et al. Investigation of ErbB-2 overexpression on patients with gastric cancer in Eastern Anatolia of Turkey. Turk J Gastroenterol 2013; 24:211-7.
18. Selcukbiricik F, Erdamar S, Buyukunal E et al. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy. Asian Pac J Cancer Prev 2014;15:10607-11.
19. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40:769-77.
20. Kataoka Y, Okabe H, Yoshizawa A, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 2013;1:84- 93
21. Ieni A, Barresi V, Branca G, et al. Changes in human epidermal growth factor receptor 2 status between primary breast/gastric carcinomas and synchronous metastatic lymph nodes: how can we explain them? J Cancer Metastasis Treat 2015;1:21-6.
22. Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects. World J Gastroenterol 2014;28;:4526-35.
23. Kim JH, Kim MA, Lee HS, et al. Comparative analysis of protein expressions in primary and metastatic gastric carcinomas. Hum Pathol 2009;40:314-22.
24. Bozzetti C, Negri F, Lagrasta C, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011;26:1372-6.
25. Perrone G, Amato M, Callea M, et al. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used? Histopathology 2012l; 61:134-5.
26. Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011;59:822-31.